The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase is Associated with Lamivudine Resistance and Enhanced Viral Replication in Vitro

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2007 Apr 18

PMID 17438047

Citations 35

Authors

Nadia Warner

Stephen Locarnini

Michael Kuiper

Angeline Bartholomeusz

Anna Ayres

Lilly Yuen

Tim Shaw

Affiliations

Soon will be listed here.

Abstract

Long-term lamivudine (LMV) treatment of chronic hepatitis B almost inevitably engenders viral resistance. Mutations that result in the replacement of the methionine at position 204 of the deoxynucleoside triphosphate-binding site of the hepatitis B virus (HBV) reverse transcriptase (rt) by isoleucine, valine, or (rarely) serine (rtM204I/V/S) confer high-level resistance to LMV but reduce replication efficiency. The subsequent selection or coselection of secondary mutations that partially restore replication efficiency is common and may influence drug resistance. Genotyping has shown that LMV treatment can select for HBV rtL80V/I mutants, but their prevalence and phenotype have not been documented. Analysis of a large sequence database revealed that rtL80V/I occurred almost exclusively in association with LMV resistance, and 85% of these isolates encoded rtL80I. Coselection of rtL80V/I occurred in 46% of isolates in which LMV resistance was attributable to rtM204I but only 9% of those in which resistance was attributable to rtM204V. Moreover, rtL80V/I did not occur in HBV genotype A isolates but occurred at similar frequencies in genotype B, C, and D isolates. In vitro phenotyping showed that although the rtL80I mutant by itself replicated less efficiently and was hypersensitive to LMV compared to the replication efficiency and sensitivity of its wild-type parent, the presence of rtL80I enhanced the replication efficiency of rt204I/V mutants without significantly affecting LMV resistance. Molecular modeling revealed that rt80 does not interact directly with the enzyme's substrates. Collectively, these results suggest that coselection of rtL80V/I and rtM204I/V occurs because the former compensates for the loss of replication efficiency associated with the acquisition of LMV resistance, particularly in the case of rtM204I.

Citing Articles

Hepatitis B Virus Genotypes and Antiviral Resistance Mutations in Romanian HIV-HBV Co-Infected Patients.

Sultana C, Casian M, Oprea C, Ianache I, Grancea C, Chiriac D Medicina (Kaunas). 2022; 58(4).

PMID: 35454370 PMC: 9028173. DOI: 10.3390/medicina58040531.

Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes.

Lee A, Cho J, Kim J, Dezhbord M, Choo S, Ahn C Int J Mol Sci. 2021; 22(4).

PMID: 33562603 PMC: 7914950. DOI: 10.3390/ijms22041606.

Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia.

Tamandjou Tchuem C, Brandt L, Nel E, Cotton M, Matthews P, Kaindjee-Tjituka F PLoS One. 2020; 15(9):e0238839.

PMID: 32915862 PMC: 7485811. DOI: 10.1371/journal.pone.0238839.

Coevolution analysis of amino-acids reveals diversified drug-resistance solutions in viral sequences: a case study of hepatitis B virus.

Teppa E, Nadalin F, Combet C, Zea D, David L, Carbone A Virus Evol. 2020; 6(1):veaa006.

PMID: 32158552 PMC: 7050494. DOI: 10.1093/ve/veaa006.

Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.

Zhang J, Wang Y, Peng Y, Qin C, Liu Y, Li J Braz J Infect Dis. 2018; 22(6):477-486.

PMID: 30586543 PMC: 9425639. DOI: 10.1016/j.bjid.2018.11.005.

References

Delaney 4th W, Yang H, Westland C, Das K, Arnold E, Gibbs C . The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003; 77(21):11833-41. PMC: 229343. DOI: 10.1128/jvi.77.21.11833-11841.2003. View

Matthews G, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E . Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS. 2006; 20(6):863-70. DOI: 10.1097/01.aids.0000218550.85081.59. View

Bartholomeusz A, Schaefer S . Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol. 2004; 14(1):3-16. DOI: 10.1002/rmv.400. View

Bartholomeusz A, Tehan B, Chalmers D . Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther. 2004; 9(2):149-60. View

Will H, REISER W, Weimer T, Pfaff E, Buscher M, Sprengel R . Replication strategy of human hepatitis B virus. J Virol. 1987; 61(3):904-11. PMC: 254036. DOI: 10.1128/JVI.61.3.904-911.1987. View

Ding J, Nanni R, Clark Jr A, Lu X, Tantillo C, Williams R . Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A. 1993; 90(13):6320-4. PMC: 46920. DOI: 10.1073/pnas.90.13.6320. View

Ganem D, Pollack J, Tavis J . Hepatitis B virus reverse transcriptase and its many roles in hepadnaviral genomic replication. Infect Agents Dis. 1994; 3(2-3):85-93. View

Schiff E, Lai C, Hadziyannis S, Neuhaus P, Terrault N, Colombo M . Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003; 38(6):1419-27. DOI: 10.1016/j.hep.2003.09.040. View

Lau D, Khokhar M, Doo E, Ghany M, Herion D, Park Y . Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000; 32(4 Pt 1):828-34. DOI: 10.1053/jhep.2000.17912. View

10.

Ono S, Kato N, Shiratori Y, Kato J, Goto T, Schinazi R . The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest. 2001; 107(4):449-55. PMC: 199250. DOI: 10.1172/JCI11100. View

11.

Stuyver L, Locarnini S, Lok A, Richman D, Carman W, Dienstag J . Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001; 33(3):751-7. DOI: 10.1053/jhep.2001.22166. View

12.

Delaney 4th W, Edwards R, Colledge D, Shaw T, Torresi J, Miller T . Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother. 2001; 45(6):1705-13. PMC: 90535. DOI: 10.1128/AAC.45.6.1705-1713.2001. View

13.

Delaney 4th W, Locarnini S, Shaw T . Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother. 2001; 12(1):1-35. DOI: 10.1177/095632020101200101. View

14.

Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T . In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother. 2001; 45(9):2495-501. PMC: 90683. DOI: 10.1128/AAC.45.9.2495-2501.2001. View

15.

Gaillard R, Barnard J, Lopez V, Hodges P, Bourne E, Johnson L . Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob Agents Chemother. 2002; 46(4):1005-13. PMC: 127103. DOI: 10.1128/AAC.46.4.1005-1013.2002. View

16.

Torresi J, Earnest-Silveira L, Civitico G, Walters T, Lewin S, Fyfe J . Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology. 2002; 299(1):88-99. DOI: 10.1006/viro.2002.1448. View

17.

Suk F, Lin M, Newman M, Pan S, Chen S, Liu J . Replication advantage and host factor-independent phenotypes attributable to a common naturally occurring capsid mutation (I97L) in human hepatitis B virus. J Virol. 2002; 76(23):12069-77. PMC: 136898. DOI: 10.1128/jvi.76.23.12069-12077.2002. View

18.

Chen R, Edwards R, Shaw T, Colledge D, Delaney 4th W, Isom H . Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology. 2002; 37(1):27-35. DOI: 10.1053/jhep.2003.50012. View

19.

Aye T, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J . Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol. 1997; 26(5):1148-53. DOI: 10.1016/s0168-8278(97)80125-0. View

20.

Wrobel J, Chao S, Conrad M, Merker J, Swanstrom R, Pielak G . A genetic approach for identifying critical residues in the fingers and palm subdomains of HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A. 1998; 95(2):638-45. PMC: 18473. DOI: 10.1073/pnas.95.2.638. View